Dyax Launches HAE Diagnostic Testing Refund Program to Encourage Proper Diagnosis and Disease Management
10:45 EDT 24 May 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Dyax
Corp. (NASDAQ: DYAX) the manufacturer of KALBITOR® (ecallantide) for
the treatment of acute attacks of hereditary angioedema (HAE) in
patients 16 years of age and older, has announced the launch of its HAE
diagnosti...
Other Sources for this Article
Dyax Corp.
George Migausky, 617-250-5733
Executive Vice
President and Chief Financial Officer
gmigausky@dyax.com
or
Jennifer
Harsey, 617-250-5741
Manager, Investor Relations and
Corporate
Communications
jharsey@dyax.com
More From BioPortfolio on "Dyax Launches HAE Diagnostic Testing Refund Program to Encourage Proper Diagnosis and Disease Management"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
